Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14223540 | 1.00 | KMT2A (0.60) | KMT2ATRPM8MEN1KDM4EALDH1A1 | |
| SCHEMBL867252 | 0.84 | TRPM8 (0.62) | KMT2ATRPM8MEN1KDM4EALDH1A1 | |
| SCHEMBL22146777 | 0.83 | KMT2A (0.46) | KMT2ATRPM8MEN1KDM4EALDH1A1 | |
| SCHEMBL18676293 | 0.82 | KMT2A (0.67) | KMT2ATRPM8MEN1KDM4EALDH1A1 | |
| SCHEMBL34472268 | 0.82 | KMT2A (0.67) | KMT2ATRPM8MEN1KDM4EALDH1A1 | |
| SCHEMBL19248407 | 0.82 | KMT2A (0.67) | KMT2ATRPM8MEN1KDM4EALDH1A1 | |
| SCHEMBL17520458 | 0.82 | KMT2A (0.67) | KMT2ATRPM8MEN1KDM4EALDH1A1 | |
| SCHEMBL11884302 | 0.81 | KMT2A (0.63) | KMT2ATRPM8MEN1KDM4EALDH1A1 | |
| SCHEMBL18813884 | 0.81 | TRPM8 (0.58) | KMT2ATRPM8MEN1KDM4EALDH1A1 | |
| SCHEMBL19138937 | 0.79 | KMT2A (0.73) | KMT2ATRPM8MEN1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9974782-B2 | Phosphodiesterase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170216275-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-03 | — | — | US | disclosed |
| US-20160314241-A1 | DRUG DISCOVERY METHOD | Keddem Bioscience Ltd. (IL) | 2016-10-27 | — | — | US | disclosed |
| US-20160314241-A1 | DRUG DISCOVERY METHOD | Keddem Bioscience Ltd. (IL) | 2016-10-27 | — | — | US | disclosed |
| US-20160314241-A1 | DRUG DISCOVERY METHOD | Keddem Bioscience Ltd. (IL) | 2016-10-27 | — | — | US | disclosed |
| US-9422242-B2 | Phosphodiesterase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-08-23 | — | — | US | disclosed |
| US-9405885-B2 | Drug discovery method | Keddem Bioscience Ltd. (IL) | 2016-08-02 | — | — | US | disclosed |
| US-9405885-B2 | Drug discovery method | Keddem Bioscience Ltd. (IL) | 2016-08-02 | — | — | US | disclosed |
| US-9405885-B2 | Drug discovery method | Keddem Bioscience Ltd. (IL) | 2016-08-02 | — | — | US | disclosed |
| US-20150080394-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | COLUMBIA UNIVERSITY (US) | 2015-03-19 | — | — | US | disclosed |
| US-20110237458-A1 | DRUG DISCOVERY METHOD | Keddem Bioscience Ltd. (IL) | 2011-09-29 | — | — | US | disclosed |
| US-20110237458-A1 | DRUG DISCOVERY METHOD | Keddem Bioscience Ltd. (IL) | 2011-09-29 | — | — | US | disclosed |
| US-20110237458-A1 | DRUG DISCOVERY METHOD | Keddem Bioscience Ltd. (IL) | 2011-09-29 | — | — | US | disclosed |
| US-8019550-B2 | Drug discovery method | Keddem Bioscience Ltd. (IL) | 2011-09-13 | — | — | US | disclosed |
| US-8019550-B2 | Drug discovery method | Keddem Bioscience Ltd. (IL) | 2011-09-13 | — | — | US | disclosed |
| EP-2324886-A1 | Novel deuterated analogues of tadalafil | Concert Pharmaceuticals Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-1289989-A2 | DERIVATIVES OF 2,3,6,7,12,12A-HEXAHYDROPYRAZINO[1',2':1,6]PYRIDO[3,4-B]INDOLE-1,4-DIONE | Lilly Icos LLC (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001094345-A3 | DERIVATIVES OF 2,3,6,7,12,12A-HEXAHYDROPYRAZINO[1',2':1,6]PYRIDO[3,4-B]INDOLE-1,4-DIONE | LILLY ICOS LLC (US) | 2002-07-18 | — | — | WO | disclosed |
| WO-2001094345-A2 | DERIVATIVES OF 2,3,6,7,12,12A-HEXAHYDROPYRAZINO[1',2':1,6]PYRIDO[3,4-B]INDOLE-1,4-DIONE | LILLY ICOS LLC (US) | 2001-12-13 | — | — | WO | disclosed |
| US-3917599-A | 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles | COUNCIL SCIENT IND RES | 1975-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080394-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE7A, PDE5A, PDE4A | KMT2A 3277/4885TRPM8 3098/4885MEN1 1930/4885 |
| US-20170216275-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE7A, PDE5A, PDE4A | KMT2A 3277/4885TRPM8 3098/4885MEN1 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.